ANIX Overview

Anixa Biosciences, Inc. is a biotechnology company. The Company is developing therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics program consists of the development of liraltagene autoleucel (lira-cel), a chimeric endocrine receptor-T cell therapy, which is a novel form of chimeric antigen receptor-T cell (CAR-T) technology, initially focused on treating ovarian cancer, that is being developed of its subsidiary, Certainty Therapeutics, Inc. (Certainty). Its vaccine programs include the development of a vaccine against breast cancer, the development of a vaccine against ovarian cancer, and a vaccine discovery program utilizing the same mechanism of its breast and ovarian cancer vaccines to develop additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon and prostate. It is also developing a method to vaccinate women against breast cancer, focused on triple-negative breast cancer.

Wall Street analysts forecast ANIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANIX is10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Anixa Biosciences Inc revenue for the last quarter amounts to 0.00 USD, decreased

Anixa Biosciences Inc. EPS for the last quarter amounts to -0.08 USD, decreased -20.00

Anixa Biosciences Inc (ANIX) has 4 emplpoyees as of May 23 2026.

Today ANIX has the market capitalization of 92.20M USD.